Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$627 Mln
Revenue (TTM)
$191 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
14
P/B Ratio
1.8
Industry P/E
--
EV/EBITDA
6.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0.8
Face value
--
Shares outstanding
54,596,900
CFO
$-269.46 Mln
EBITDA
$-403.34 Mln
Net Profit
$-379.73 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
| 8.9 | 7.8 | 99.8 | -8.5 | -6.1 | -12.2 | -- |
|
BSE Sensex
| 7.0 | 1.9 | 14.5 | 4.6 | 15.6 | 17.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
| 108.4 | -43.0 | -61.5 | -61.3 | 118.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
|
12.0 | 626.8 | 190.9 | 50.3 | 19.2 | 17.3 | 14 | 1.8 |
| 52.7 | 8,330.6 | 1,208.8 | 131.7 | 13.4 | 6.3 | 64 | 4.1 | |
| 128.4 | 8,299.9 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 158.4 | 7,717.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.4 | |
| 53.5 | 10,065.7 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 43.5 | 12,585.5 | 2,298.9 | 643.6 | 35.4 | 29.2 | 21.1 | 5.9 | |
| 322.5 | 9,240.4 | 2,156.6 | 416.4 | 21.2 | 56.5 | 24.6 | 15.6 | |
| 32.5 | 11,791.8 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.2 | |
| 128.7 | 12,777.5 | 2,412.6 | 305.8 | 20.5 | 11.6 | 43.9 | 5.0 | |
| 294.4 | 13,283.4 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.7 | 2.0 |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene... Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Address: 45 Wiggins Avenue, Bedford, MA, United States, 01730 Read more
CEO & Director
Dr. Edward M. Kaye M.D., Ph.D.
CEO & Director
Dr. Edward M. Kaye M.D., Ph.D.
Headquarters
Bedford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Stoke Therapeutics Inc (STOK) stood at $ 452 Mln as on 31-Mar-25
The share price of Stoke Therapeutics Inc (STOK) is $12.01 (NASDAQ) as of 08-Jul-2025 16:00 EDT. Stoke Therapeutics Inc (STOK) has given a return of -6.07% in the last 3 years.
Stoke Therapeutics Inc (STOK) has a market capitalisation of $ 627 Mln as on 07-Jul-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Stoke Therapeutics Inc (STOK) is 1.79 times as on 07-Jul-2025, a 42% discount to its peers’ median range of 3.08 times.
The P/E ratio of Stoke Therapeutics Inc (STOK) is 14.00 times as on 07-Jul-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Stoke Therapeutics Inc (STOK) and enter the required number of quantities and click on buy to purchase the shares of Stoke Therapeutics Inc (STOK).
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Address: 45 Wiggins Avenue, Bedford, MA, United States, 01730
The CEO & director of Dr. Edward M. Kaye M.D., Ph.D.. is Stoke Therapeutics Inc (STOK), and CFO & Sr. VP is Dr. Edward M. Kaye M.D., Ph.D..
There is no promoter pledging in Stoke Therapeutics Inc (STOK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,332
|
|
|
1,281
|
|
|
1,208
|
|
|
1,171
|
|
|
1,016
|
|
|
937
|
|
|
834
|
|
|
829
|
|
|
774
|
| Stoke Therapeutics Inc. (STOK) | Ratios |
|---|---|
|
Return on equity(%)
|
17.27
|
|
Operating margin(%)
|
19.16
|
|
Net Margin(%)
|
26.33
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Stoke Therapeutics Inc (STOK) was $0 Mln.
$0.32
(
